DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
The instant application was filed 6/11/2024. This application claims benefit to foreign application JAPAN 2023-104917, filed 6/27/2023. Claims 1-25 are pending.
Election/Restrictions
Applicant’s election without traverse of Group I, claims 1-10, in the reply filed on 7/28/2026 is acknowledged. Claims 11-25 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-10 have been examined on the merits.
Information Disclosure Statement
The information disclosure statement submitted on 8/7/2024 has been considered by the examiner.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
The term “mid-infrared region” in claim 1 is a relative term which renders the claim indefinite. The term “mid-infrared region” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Claims 2-10 depend from claim 1 and do not remedy the indefiniteness; hence, claims 1-10 are rejected under 35 U.S.C. 112(b) as being indefinite.
A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 3 recites the broad recitation “the culture container is N culture dishes”, and the claim also recites “(N is an integer of 2 or more)” which is the narrower statement of the range/limitation. The claim is considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims because it is unclear whether parenthetical expressions are optional or required; thus, claim 3 is rejected under 35 U.S.C. 112(b) as being indefinite.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-10 are rejected under 35 U.S.C. 103 as being unpatentable over Takebe et al., US 2018/0236257 (cite A, attached PTO-892; herein “Takebe”) in view of Larson et al., 2021 (second NPL cite, IDS, 8/7/2024; herein “Larson”) and Weichselbaum et al., 2002 (cite U, attached PTO-892; herein “Parney”).
Takebe teaches methods of cell stimulation comprising irradiating cells cultured on a culture container (Abst.; [0028]; Fig. 1) with mid-infrared light with a wavelength of 4-10 µm, i.e., a cell sample evaluation method for evaluating a culture state of an object cell sample of an evaluation object containing a plurality of cells cultured on a culture container, the evaluation method comprising: an evaluation light irradiation step of irradiating an irradiation region set in a culture region of the plurality of cells in the object cell sample with evaluation light having a wavelength in a mid-infrared region under a predetermined irradiation condition.
Takebe teaches that infrared photon energy has the capacity to kill or damage cells ([0002-0008]). Additionally, Larson discloses that mid-infrared light of 3-30 µm is the most attractive spectral region for killing viable cells, i.e., for ablating soft or hard tissues (Abst.). Hence, a person of ordinary skill in the art at the time of filing would have found it obvious to correlate irradiation with different intensities, wavelength and exposure time with death of the irradiated cells in order to practice the cell sample evaluation method with assurance that the irradiated cells will not be killed by the mid-infrared irradiation.
Neither Takebe nor Larson teaches methods of quantifying cell death resulting from the mid-infrared irradiation; however, a person of ordinary skill in the art at the time of filing would have found it obvious to quantify the dead cells by staining a culture of the cells with a stain that selectively stains dead cells in view of the disclosure of Weichselbaum.
Weichselbaum is drawn to combining low doses of irradiation with a chemotherapeutic (chelerythine) in order to increase apoptosis in tumor cells (Abst.) Weichselbaum teaches assaying cell death after irradiation comprising staining cells with propidium iodide which selectively stains dead cells (col. 15, ll. 18-48).
Hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice the method made obvious by Takebe in view of Larson and Weichselbaum comprising irradiating cell samples in culture plates with mid-infrared light with different intensities and/or exposure times; measure the dead cells in the irradiated areas with propidium iodide which is excluded from live, viable cells but stains dead cells; and analyze the correlation between the irradiation amount and the dead cell number and compare the correlation to reference samples with a known state; therefore, claims 1-3, 5-8 and 10 are prima facie obvious.
Regarding claim 4, passage number is related to senescence of cells, i.e., highly passaged cells are more susceptible to senescence; hence, a person of ordinary skill in the art at the time of filing would have found it obvious to correlate the resistance to death from irradiation with the passage number of the irradiated cells; therefore, claim 4 is prima facie obvious.
Regarding claim 9, the correlation of irradiation with cell death would be expected to produce a curve, e.g., a straight line, correlating the amount of irradiation with the amount of cell death with a threshold irradiation amount for generating dead cells; therefore, claim 9 is prima facie obvious.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-3, 5-8 and 10 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 and 7-8 of copending Application No. 18/739556 (reference application; herein “’556”).
Although the claims at issue are not identical, they are not patentably distinct from each other because claim 1 of ‘556 recites a cell sample measurement method comprising: a preparation step of placing an object cell sample of a measurement object containing a plurality of cells cultured on a culture dish on a sample stage; an evaluation light irradiation step of irradiating N irradiation regions (N is an integer of 2 or more) set by dividing a culture region of the plurality of cells in the object cell sample with evaluation light having a wavelength in a mid-infrared region supplied from an irradiation light source with irradiation amounts different from each other; a dead cell number measurement step of measuring a dead cell number generated according to the irradiation amount of the evaluation light in each of the N irradiation regions of the object cell sample; and a culture state analysis step of obtaining, for the object cell sample, an object correlation between the irradiation amount of the evaluation light and the dead cell number for the N irradiation regions serving as an index of evaluation of a culture state of the object cell sample; hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice a cell sample evaluation method for evaluating a culture state of an object cell sample of an evaluation object containing a plurality of cells cultured on a culture container wherein the culture container comprises a culture dish; the evaluation method comprising: an evaluation light irradiation step of irradiating an irradiation region set in a culture region of the plurality of cells in the object cell sample with evaluation light having a wavelength in a mid-infrared region under a predetermined irradiation condition; a dead cell number measurement step of measuring a dead cell number generated according to an irradiation amount of the evaluation light in the irradiation region of the object cell sample; and a culture state analysis step of evaluating a culture state of the object cell sample by obtaining an object correlation between the irradiation amount of the evaluation light and the dead cell number for the object cell sample, and comparing a reference correlation between the irradiation amount of the evaluation light and the dead cell number for a reference cell sample with a known culture state and the object correlation; therefore instant claims 1-2 are prima facie obvious.
Regarding instant claim 3, the claims of ‘556 do not specifically recite more than one culture dish; however, claim 1 of ‘556 recites dividing a culture region of the plurality of cells in the object cell sample with evaluation light having a wavelength in a mid-infrared region supplied from an irradiation light source with irradiation amounts different from each other; hence, a person of ordinary skill in the art at the time of filing would have found it obvious for the divided culture regions to be in different culture dishes, i.e., N culture dishes and for the N irradiation regions to be set in the culture region on each of the N culture dishes; therefore, instant claim 3 is prima facie obvious.
Claim 5 of ‘556 recites the cell sample measurement method according to Claim 1, wherein in the dead cell number measurement step, the dead cell number is measured by capturing an optical image of the object cell sample stained with a staining agent for selectively staining dead cells; hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice the method made obvious by claim 1 of ‘556 wherein in the dead cell number measurement step, the dead cell number is measured by capturing an optical image of the object cell sample stained with a staining agent for selectively staining dead cells; therefore, instant claim 5 is prima facie obvious.
Claim 7 of ‘556 recites the cell sample measurement method according to Claim 1, wherein in the evaluation light irradiation step, the irradiation amount of the evaluation light is set by an irradiation condition including at least one of an irradiation time, an irradiation power, and a focusing condition of the evaluation light for the irradiation region; hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice the method made obvious by claim 1 of ‘556 wherein in the evaluation light irradiation step, the irradiation amount of the evaluation light is set by an irradiation condition including at least one of an irradiation time, an irradiation power, and a focusing condition of the evaluation light for the irradiation region; therefore, instant claim 6 is prima facie obvious.
Claim 8 of ‘556 recites cell sample measurement method according to Claim 1, wherein in the evaluation light irradiation step, the wavelength of the evaluation light is set in a wavelength region of 3 μm or more and 20 μm or less; hence, a person of ordinary skill in the art at the time of filing would have found it obvious to practice the method made obvious by claim 1 of ‘556 wherein in the evaluation light irradiation step, the wavelength of the evaluation light is set in a wavelength region of 3 μm or more and 20 μm or less; therefore, instant claim 7 is prima facie obvious.
A person of ordinary skill in the art at the time of filing would have found it obvious to compare the correlations of evaluation light and dead cell measurements from the N regions to reference correlations of evaluation light irradiation and dead cell number in reference cell samples because scientific analysis requires comparison to controls to assess the statistical significance of the results (i.e., the object correlation); hence, claims 8 and 10 are prima facie obvious.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Trent R Clarke whose telephone number is (571)272-2904. The examiner can normally be reached M-F 10-7 MST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TRENT R CLARKE/ Examiner, Art Unit 1651
/DAVID W BERKE-SCHLESSEL/ Primary Examiner, Art Unit 1651